Form 8-K - Current report:
SEC Accession No. 0001420720-25-000014
Filing Date
2025-02-19
Accepted
2025-02-19 16:25:31
Documents
15
Period of Report
2025-02-19
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20250219x8k.htm   iXBRL 8-K 33623
2 EX-99.1 ibio-20250219xex99d1.htm EX-99.1 8884
  Complete submission text file 0001420720-25-000014.txt   169862

Data Files

Seq Description Document Type Size
3 EX-101.SCH ibio-20250219.xsd EX-101.SCH 4267
4 EX-101.DEF ibio-20250219_def.xml EX-101.DEF 3990
5 EX-101.LAB ibio-20250219_lab.xml EX-101.LAB 13975
6 EX-101.PRE ibio-20250219_pre.xml EX-101.PRE 10318
17 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20250219x8k_htm.xml XML 4641
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 25640525
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)